RGD‐Modified PEG‐PAMAM‐DOX Conjugate: In Vitro and In Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells

Abstract

A novel multifunctional drug–polymer conjugate is prepared. RGD peptide is used to actively target the drug delivery system to tumor neovascular endothelial cells and tumor cells, while the PEG-PAMAM polymeric carrier permits passive targeting to the tumor site by the enhanced permeability and retention (EPR) effect. Controlled release of the anticancer drug doxorubicin is also achieved via acid-sensitive cis-aconityl linkage. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.